Nineteenth Annual Pediatric Endocrinology and Diabetes Symposium

Monday, November 9, 2020, 8:30 AM - 12:30 PM EST, Online


In light of recent advances in the care of youth with diabetes, growth disorders and other endocrinological disorders, the Mount Sinai Division of Pediatric Endocrinology and Diabetes seeks to empower a broad array of clinicians to provide the highest level of care to children with diabetes and growth disorders. Participants will learn about pathophysiology, treatment goals and methods for care of children with diabetes and growth disorders, and will emerge more confident dealing with diabetes and endocrine challenges.

1. Identify the underlying etiology of Laron syndrome, distinguish it from other growth disorders, and understand the unique properties of Laron syndrome that impact risk for diabetes and cancer.
2. Update on the changes in diagnostic practices, definitions of eligibility for GH treatment and dosing practices for newer GH preparations and other growth promoting agents.
3. Recognize health disparities in the treatment of diabetes mellitus to effect change in practice.

Practicing Physician - $30.00

MSHS Allied Health Professional - $15.00

Resident/Fellow/Medical Student - Complimentary*

**PLEASE EMAIL A COPY OF YOUR HOSPITAL ID TO [email protected] TO RECEIVE A COMPLIMENTARY REGISTRATION CODE**

Cancellation Policy

All cancellation requests must be emailed to the CME office at [email protected] by October 19, 2020. No refunds will be issued for for this course.

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (3.25 hours), Non-Physician Attendance (3.25 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Monday, November 9, 2020